

Complex Cases in VTE: Applications to Clinical Practice

References

1. Superficial Thrombophlebitis, Superficial Vein Thrombosis. August 10, 2023. Accessed May 3, 2024 at: https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=90
2. Decousus H, Prandoni P, Mismetti P, et al., for the CALISTO Study Group. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. *N Engl J Med* 2010;363:1222-1232. DOI: 10.1056/NEJMoa0912072
3. Werth S, Bauersachs R, Gerlach H, et al. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. *J Thromb Thrombolysis*. 2016 Aug;42(2):197-204. doi: 10.1007/s11239-016-1354-3. PMID: 26973347.
4. Scott G, Mahdi AJ, Alikhan R. Superficial vein thrombosis: a current approach to management. *Br J Haematol*. 2015 Mar;168(5):639-645. doi: 10.1111/bjh.13255. Epub 2014 Dec 17. PMID: 25521017.
5. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv*. 2018;2(22):3198–3225. doi: <https://doi.org/10.1182/bloodadvances.2018022954>
6. Hicks LK, Bering H, Carson KR, et al. Five Hematologic Tests and Treatments to Question. *Hematology Am Soc Hematol Educ Program*. 2014;(1):599–603. <https://doi.org/10.1182/asheducation-2014.1.599>
7. CRISTAL Study Group; Sidhu VS, Kelly TL, Pratt N, et al. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. *JAMA*. 2022 Aug 23;328(8):719-727. doi: 10.1001/jama.2022.13416. PMID: 35997730; PMCID: PMC9399863.
8. An VV, Phan K, Levy YD, Bruce WJ. Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. *J Arthroplasty*. 2016 Nov;31(11):2608-2616. doi: 10.1016/j.arth.2016.04.004. Epub 2016 Apr 13. PMID: 27178011.
9. Lassen MR, Gallus A, Raskob GE, et al., for the ADVANCE-3 Investigators. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. *N Engl J Med*. 2010;363:2487-2498. DOI: 10.1056/NEJMoa1006885
10. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. *N Engl J Med*. 2018;378:699-707. DOI: 10.1056/NEJMoa1712746

11. Mulder FI, Candeloro M, Kamphuisen PW, et al., CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. *Haematologica*. 2019 Jun;104(6):1277-1287. doi: 10.3324/haematol.2018.209114. Epub 2019 Jan 3. PMID: 30606788; PMCID: PMC6545838.
12. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2019;38(55):496-520. <https://doi.org/10.1200/JCO.19.0146>
13. Treatment of Venous Thromboembolism (VTE) in Patients with Cancer; A Pocket Guide for the Clinician. October 2023. Accessed May 4, 2024 at: <https://www.hematology.org/education/clinicians/guidelines-and-quality-care/pocket-guides>
14. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood Adv*. 2021 Apr 13;5(7):1953. doi: 10.1182/bloodadvances.2021004734. Erratum for: *Blood Adv*. 2021 Feb 23;5(4):927-974. PMID: 33821993; PMCID: PMC8045511.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.